Biorbis

The world's first and only industry-focussed Cancer Stem Cells meeting!

Dr Robert Weinberg Founding Member Whitehead Institute	Dr Pradip Majumder Scientist, Department of Oncology Merck	Paul Grayson Chief Executive Officer Fate Therapeutics
Dr. Ruggero DeMaria Research Director Istituto Superiore di Sanita and Member, Tristar Technology Group	Dr Jennie Mather Senior Vice President, Stem Cell Research MacroGenics	Dr Ram Mandalam Chief Executive Officer Cellerant Therapeutics
Dr Manish Singh Chief Executive Officer ImmunoCellular Therapeutics	Dr Vito Palombella Vice President, Drug Discovery Infinity Pharmaceuticals	Dr Tom Okarma Chief Executive Officer Geron
Dr Tim Hoey Vice President, Cancer Biology OncoMed
Dr Bin-Bing Zhou, Senior Director, Center for Integrative Biology and Biotherapeutics (CIBB), Pfizer BioPharmaceuticals Dr Jan Van Tornout, Group Director, Discovery Medicine and Clinical Pharmacology, Bristol-Myers Squibb Dr. Ruggero DeMaria, Director, Oncology & Molecular Medicine, Istituto Superiore di Sanità and Member, Tristar Technology Group Dr Markus Muenz Group Leader, EpCam Research Micromet AG Dr Venkateshwar Reddy, Group Leader, Cancer Stem Cells, Novartis Dr Erica Jackson, Scientist and Research Group Leader, Genentech Dr Sonya Zabludoff, Associate Director, Cancer Bioscience, AstraZeneca Dr Ivan Bergstein, Chief Executive Officer, Stemline Therapeutics Dr Mohamed Ragab, Global Partnering Head, Roche Dr Thomas Davis, Director of Biology/Oncology, PTC Therapeutics Dr Raymond Winquist, Vice President, Vertex Pharmaceuticals Dr Agamemnon Epenetos, Chairman, Trojantec Dr Brent Cochran, Principle Investigator, Tufts University Dr Stephen Gillies, Founder, President and Chief Executive Officer, Provenance Bio

Understanding and targeting cancer stem cells represents a revolutionary, game-changing prospect for the pharmaceutical and biotech industry.

The world's first and only commercially-focussed Cancer Stem Cells meeting provides a unique opportunity for oncology business/research leaders and scientists to assess the potential of cancer stem cells for your business and research.

And for those companies and people already focussing on cancer stem cells, this is the world's largest and best industry-focused event where you can meet the people and companies making it happen.

Why attend?

• Understand efforts of big pharma and large biotech companies like Pfizer, Genentech, MedImmune, Novartis, Bristol-Myers Squibb, Merck, AstraZeneca and Roche in targeting cancer stem cells
• Listen to the world's most innovative biotechs such as OncoMed, Geron, Stemline Therapeutics, ImmunoCellular Therapeutics, Micromet, Fate Therapeutics and Cellerant Therapeutics outline how they are attacking or preventing cancer stem cells from taking hold, along with the very latest clinical updates
• Hear pioneering research leaders and scientists, including Dr Robert Weinberg of the Whitehead Institute and Dr Piyush Gupta of the Broad Institute
• Get critical perspectives on your research from the brightest minds working in the cancer stem cells field
• Build an unrivalled network of contacts all researching and developing drugs targeting cancer stem cells.

But don't just listen to these leading companies and speakers.

Meet them.

Don't miss this chance to discuss your research and business with the largest ever collection of industry cancer stem cells companies and specialists all under one roof.

1-2-1 Partnering

We work harder than any other meeting organizer to put you in front of the individuals you want to meet, providing personal introductions and a host of other networking opportunities including:

• Speed networking – Meet up to 50 other attendees in a one hour session. Introduce yourself to potential partners, collaborators and clients.
• Over 8 hours of networking time built into the agenda
• Innovative masterclasses providing you with the chance to get tailored solutions to the challenges you're facing.
• Panel discussion – interactive Q&A sessions giving you an opportunity to join the discussion.